DeZwarteRidder schreef op 18 september 2019 08:11:
Under the up to EUR 20 million Yorkville convertible notes financing facilitythat was originally implemented in October 2018, Curetis in May 2019 received access to another EUR 1.5 million gross in funding.Net proceeds from this tranche,which was provided in June 2019,wereEUR 1.36 million. As with the prior tranche, Yorkville is expected from time to time to convert such notes into equity and Curetis will then issue new shares. For further details on the Yorkville convertible notes facility, please also see the “Convertibles” section under:
curetis.com/investors/#corporate-gove...Key Financials H1-2019
Revenues: EUR 1.09 million(up by almost 35% compared to EUR 807k in the first half-year 2018).
Expenses:EUR 11.49milliontotal cost of sales, distribution costs, administrative expenses and research & development expenses (vs. EUR 12.44millionin the first half-year 2018). The decrease is mainly based on the successful implementation of
the recent re-organization and reduction in organizational size, complexity and staffing levels as well as R&D pipeline and commercial channel partnering and revised commercial strategy.These expenses in H1-2019 include EUR 1,242k in write-downs on inventory in Unyvero systems which had no cash flow impact.
Operating loss:EUR10.28million(vs. EUR-11.37 millionin the first half-year 2018).
Net loss of the period:EUR-11.08 million (vs. EUR-11.56millionin the half-year 2018).
Cash and cash equivalents:EUR 7.81millionof June 30, 2019(vs. EUR 10.28millionas of December 31, 2018).
Net cash burnin the first six months ended June 30, 2019,was EUR -2.49 million -i.e. a reduction by 47.5% compared to the first six months 2018.